At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 12 enrolled
Drug / intervention
Cyclophosphamide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Clinical Trial of PD-1 Knockout Engineered T Cells Treating Patients With Advanced Non-small Cell Lung Cancer
In Brief
A Phase 1 clinical trial evaluating Cyclophosphamide and PD-1 Knockout T Cells for Metastatic Non-small Cell Lung Cancer. Completed, enrolled 12 participants across 1 site.
Detailed Summary
This study will evaluate the safety of PD-1 knockout engineered T cells in treating metastatic non-small cell lung cancer. Blood samples will also be collected for research purposes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Non-small Cell Lung Cancer
CountriesChina
CollaboratorsChengdu MedGenCell, Co., Ltd.
Timeline
Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedJun 2016
Enrollment StartAug 2016
Primary CompletionAug 2018
Study CompletionMar 2020
TodayJul 2026
First PostedJun 8, 2016
Enrollment StartAug 26, 2016
Primary CompletionAug 20, 2018
Study CompletionMar 17, 2020
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 10.1 years ago
Interventions
Cyclophosphamidedrug
To deplete Tregs before collecting peripheral blood
PD-1 Knockout T Cellsother
Autologous lymphocytes are collected and PDCD1 gene is knocked out in the laboratory. Cells are selected and expanded ex vivo. Cells are infused back to the patients for treatment